Crescendo Biologics Overview
- Year Founded
-
2007

- Status
-
Private
- Employees
-
38

- Latest Deal Type
-
2ndary - Private
- Investors
-
18
Crescendo Biologics General Information
Description
Operator of a clinical-stage immuno-oncology company intended to develop potent, multi-functional human body therapeutics in oncology. The company specializes in multi-functional drugs based on its patent-protected, transgenic mouse platform generating fully human viewport height domain building blocks, enabling researchers to build medicines capable of delivering safe durable responses to patients.
Contact Information
Website
www.crescendobiologics.comCorporate Office
- Meditrina Building 260
- Babraham Research Campus
- Cambridge CB22 3AT
- England, United Kingdom
Corporate Office
- Meditrina Building 260
- Babraham Research Campus
- Cambridge CB22 3AT
- England, United Kingdom
Crescendo Biologics Timeline
Crescendo Biologics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
12. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
11. Later Stage VC | 24-Jul-2023 | Completed | Clinical Trials - Phase 1 | |||
10. Debt - General | 01-Jan-2023 | Completed | Clinical Trials - Phase 1 | |||
9. Later Stage VC | 10-Jan-2022 | Completed | Clinical Trials - Phase 1 | |||
8. Later Stage VC | 15-Feb-2021 | Completed | Clinical Trials - Phase 1 | |||
7. Later Stage VC (Series B) | 30-Apr-2018 | Completed | Clinical Trials - Phase 1 | |||
6. Later Stage VC | 10-Oct-2016 | Completed | Clinical Trials - Phase 1 | |||
5. Grant | 27-May-2015 | Completed | Clinical Trials - Phase 1 | |||
4. Later Stage VC (Series A) | 03-Apr-2014 | $33.7M | $46.1M | Completed | Clinical Trials - Phase 1 | |
3. Later Stage VC | 05-Oct-2012 | $5.17M | $12.4M | Completed | Clinical Trials - Phase 1 |
Crescendo Biologics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B Preferred | ||||||||
Series B Preferred | ||||||||
Series B Preferred | ||||||||
Series A | ||||||||
Series A Preferred | 648,426 | $0.000013 | $1.18 | $1.18 | 1x | $1.18 | 0.39% | |
Series A | 4,695,000 | $0.000013 | $1.34 | $1.34 | 1x | $1.34 | 2.81% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Crescendo Biologics Comparisons
Industry
Financing
Details
Crescendo Biologics Competitors (66)
One of Crescendo Biologics’s 66 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
Memo Therapeutics | Venture Capital-Backed | Schlieren, Switzerland | ||||
Pathios Therapeutics | Venture Capital-Backed | Abingdon, United Kingdom | ||||
Nektar Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
Ncardia | Venture Capital-Backed | Leiden, Netherlands |
Crescendo Biologics Patents
Crescendo Biologics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
GB-202319982-D0 | Therapeutic molecules | Pending | 22-Dec-2023 | ||
GB-202317996-D0 | Combination therapy | Pending | 24-Nov-2023 | ||
GB-202317997-D0 | Therapeutic molecules | Pending | 24-Nov-2023 | ||
GB-202315938-D0 | Therapeutic molecules | Pending | 18-Oct-2023 | ||
GB-202205589-D0 | Mesothelin binders | Inactive | 14-Apr-2022 | C07K16/28 |
Crescendo Biologics Signals
Crescendo Biologics Investors (18)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Kreos Capital | Lender/Debt Provider | Minority | ||
BioNTech | Corporation | Minority | ||
Andera Partners | PE/Buyout | Minority | ||
IP Group | Venture Capital | Minority | ||
Quan Capital | Venture Capital | Minority |
Crescendo Biologics FAQs
-
When was Crescendo Biologics founded?
Crescendo Biologics was founded in 2007.
-
Where is Crescendo Biologics headquartered?
Crescendo Biologics is headquartered in Cambridge, United Kingdom.
-
What is the size of Crescendo Biologics?
Crescendo Biologics has 38 total employees.
-
What industry is Crescendo Biologics in?
Crescendo Biologics’s primary industry is Drug Discovery.
-
Is Crescendo Biologics a private or public company?
Crescendo Biologics is a Private company.
-
What is Crescendo Biologics’s current revenue?
The current revenue for Crescendo Biologics is
. -
How much funding has Crescendo Biologics raised over time?
Crescendo Biologics has raised $274M.
-
Who are Crescendo Biologics’s investors?
Kreos Capital, BioNTech, Andera Partners, IP Group, and Quan Capital are 5 of 18 investors who have invested in Crescendo Biologics.
-
Who are Crescendo Biologics’s competitors?
Adaptimmune Therapeutics, Memo Therapeutics, Pathios Therapeutics, Nektar Therapeutics, and Ncardia are some of the 66 competitors of Crescendo Biologics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »